RELAPSING POLYCHONDRITIS AWARENESS… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2014

Legal Domicile

Principal Officer

DAVID BAMMERT

Phone

9062251166

Tax Period

2024-04-01 to 2025-03-31

RELAPSING POLYCHONDRITIS AWARENESS AND SUPPORT FOUNDATION INC, founded in 2014, is a community nonprofit in the Diseases & Disorders sector that reported $1.3M in total revenue in fiscal year 2024. Revenue surged 109% from the prior year, signaling strong growth momentum. The organization ran a surplus of $355K, a strong 26% operating margin.

Mission

THE RP FOUNDATION'S MISSION IS TO: (A) INCREASE AWARENESS ABOUT RELAPSING POLYCHONDRITIS; (B) PROVIDE SUPPORT (PRIMARILY THROUGH THE USE OF THE INTERNET, SOCIAL MEDIA, AND PATIENT ADVOCACY PROGRAMS) FOR THOSE WHO ARE AFFECTED BY RELAPSING POLYCHONDRITIS, SUPPORT RESEARCH TO ADVANCE A CURE FOR RELAPSING POLYCHONDRITIS; (C) PROMOTE QUALITY CARE FOR RELAPSING POLYCHONDRITIS PATIENTS; AND (D) ENGAGE IN SUCH OTHER ACTIVITIES IN CONNECTION THEREWITH THAT THE BOARD OF DIRECTORS MAY AUTHORIZE, IN ALL CASES SUBJECT TO THE PROVISION OF SECTION 501(C)(3) OF THE INTERNAL REVENU CODE OF 1986, AS AMENDED, OR THE CORRESPONDING PROVISIONS OF ANY SUBSEQUENT FEDERAL TAX LAW (THE "CODE").

Program Service Accomplishments

Program 1

Expenses: $53,019

AWARENESS: THE RP FOUNDATION AMPLIFIED ITS MISSION TO THE BROADER COMMUNITY THROUGH STRATEGIC PARTNERSHIPS, INCLUDING COLLABORATION WITH RACE FOR RP AND SIX INTERNATIONAL MOTORSPORTS TEAMS. THIS...

AWARENESS: THE RP FOUNDATION AMPLIFIED ITS MISSION TO THE BROADER COMMUNITY THROUGH STRATEGIC PARTNERSHIPS, INCLUDING COLLABORATION WITH RACE FOR RP AND SIX INTERNATIONAL MOTORSPORTS TEAMS. THIS INCLUDED THE CREATION OF THE AWARD- WINNING "RACE OF OUR LIVES DOCUMENTARY" IN 2023. THE DOCUMENTARY, A SEQUEL TO THE 2018 "RIDE OF MY LIFE" FILM, RECEIVED MULTIPLE ACCOLADES IN FY25, INCLUDING BEST DOCUMENTARY FEATURE AT THE LOS ANGELES MOVIE AWARDS AND THE SOCAL FILM AWARDS. FOCUSED ON A PATIENT'S JOURNEY WITH RELAPSING POLYCHONDRITIS, THE FILM WAS PRAISED FOR ITS POWERFUL STORYTELLING. CONCURRENTLY, THE FOUNDATION SIGNIFICANTLY INCREASED AWARENESS AND SUPPORT FOR ITS INNOVATIVE RP AND AUTOIMMUNE RESEARCH THROUGH ROBUST DIGITAL COMMUNICATIONS, UTILIZING PLATFORMS LIKE YOUTUBE, ENEWSLETTER, AND SOCIAL MEDIA CHANNELS (X, FACEBOOK, AND INSTAGRAM). THESE EFFORTS RESULTED IN SUBSTANTIAL FOLLOWER GROWTH ACROSS ALL SOCIAL MEDIA PLATFORMS.

Program 2

Expenses: $794,008

RESEARCH: THE RP FOUNDATION'S COMMITMENT TO ADVANCING RESEARCH IN RELAPSING POLYCHONDRITIS (RP) AND RELATED AUTOIMMUNE DISEASES YIELDED SIGNIFICANT PROGRESS IN FY25. THROUGH THE FOUNDATION'S ONGOING FINANCIAL SUPPORT, THE PENN MEDICINE RP PROGRAM NOT ONLY PROVIDED HIGHLY INDIVIDUALIZED, MULTIDISCIPLINARY CARE TO RP PATIENTS BUT ALSO SIGNIFICANTLY EXPANDED ITS RESEARCH INFRASTRUCTURE. THE PROGRAM'S COLLABORATION WITH THE VASCULITIS CLINICAL RESEARCH CONSORTIUM (VCRC) LONGITUDINAL STUDY PROVED VITAL IN GROWING BOTH ITS CLINICAL AND RESEARCH ENDEAVORS. KEY RESEARCH ACTIVITIES IN FY25 INCLUDED: "THE NASAL MICROBIOME IN ANCA ASSOCIATED VASCULITIS AND RELAPSING POLYCHONDRITIS (NMB) STUDY. "THE PROSPECT CLINICAL TRIAL (NCT06941376) - A PILOT STUDY EXAMINING IMMUNOMODULATORY MEDICATIONS FOR RP. A MAJOR DEVELOPMENT IN FY25 WAS THE ESTABLISHMENT OF THE REDEFINING AUTOIMMUNE DISEASES ACROSS RHEUMATOLOGY (RADAR) RP PROGRAM, FOCUSED ON CHARACTERIZING AUTOIMMUNITY IN RP PATIENTS. THIS PROGRAM HOLDS THE PROMISE OF ACCELERATING DIAGNOSES, TAILORING TREATMENTS, AND DEVELOPING INNOVATIVE TARGETED IMMUNOTHERAPIES FOR RP BY IDENTIFYING CRITICAL INFLAMMATORY CELLS AND SERUM MARKERS. FURTHER UNDERSCORING ITS DEDICATION, THE RP FOUNDATION INVESTED IN AN RP FELLOW AT PENN MEDICINE TO FURTHER SPECIALIZED RP RESEARCH, ULTIMATELY AIMING TO CULTIVATE AN RO1-LEVEL RELAPSING POLYCHONDRITIS RESEARCHER. THE RP FOUNDATION PLAYED A CRUCIAL ROLE IN THE SUCCESSFUL LAUNCH AND CONTINUED GROWTH OF THE PURPOSE BIOBANK AT ALLEGHENY HEALTH NETWORK, WHICH BEGAN IN 2024. IN FISCAL YEAR 2025 ALONE, THE BIOBANK WELCOMED 106 PARTICIPANTS FROM 24 STATES AND PUERTO RICO, INCLUDING 66 PATIENTS WITH RP. THIS LED TO THE COLLECTION OF 88 BLOOD SAMPLES, WHICH ARE NOW STORED FOR VITAL FUTURE RESEARCH INTO RP AND RELATED AUTOIMMUNE DISEASES.

Program 3

Expenses: $23,897

EDUCATION: THE RP FOUNDATION AND RACE FOR RP ARE INSPIRED BY THE COURAGE AND RESILIENCE OF INDIVIDUALS WITH RELAPSING POLYCHONDRITIS (RP). THROUGH A RAPIDLY EXPANDING NETWORK OF PATIENTS, DONORS, AND RESEARCHERS, UNIQUE OPPORTUNITIES ARE CREATED TO ADVANCE DISCOVERIES IN RP AND RELATED AUTOIMMUNE DISEASES. IN FY25, THE PENN DIVISION OF RHEUMATOLOGY AND RP PROGRAM, WITH RP FOUNDATION SUPPORT, HELD AN EDUCATIONAL MEETING FOR RP PATIENTS AND THEIR FAMILIES, FACILITATING COMMUNITY BUILDING, EXPERT INTERACTION, AND LEARNING ABOUT RP. THE RP FOUNDATION HIGHLIGHTED ITS RP- FOCUSED RESEARCH INVESTMENTS AND PENN COLLABORATION AT THIS MEETING IN OCTOBER 2024. FURTHERMORE, THE PENN VASCULITIS CENTER / PENN RP PROGRAM, WITH SUPPORT FROM THE RP FOUNDATION AND OTHER PARTNERS, HOSTED DR. ROGER YANG, A VASCULITIS FOUNDATION FELLOW. DR. YANG PROVIDED PATIENT CARE AND WAS INSTRUMENTAL IN CONTRIBUTING TO THE VCRC'S DATABASE REGARDING THE CLINICAL CHARACTERISTICS OF RP AND TREATMENT APPROACHES. HE INTENDS TO OPEN A NEW ACADEMIC VASCULITIS CENTER IN MONTREAL, WHERE HE WILL CONTINUE TO CARE FOR RP PATIENTS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $1,331,631

Program Service Revenue $0

Investment Income $10,408

Other Revenue $0

TOTAL REVENUE $1,342,039

Expense Breakdown

Grants Paid $125,319

Salaries & Benefits $118,863

Fundraising Expenses $23,773

Program Expenses $870,924

Other Expenses $742,578

TOTAL EXPENSES $986,760

Year-over-Year Comparison

	2024	2023	Change
Revenue	$1,342,039	$641,371	+1.1%
Expenses	$986,760	$881,363	+0.1%
Net Income	$355,279	$-239,992	-2.5%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$100,000

Total Directors